The current price of FDMT is $12.28 — it has increased by 2.76% since the previous close. Data as of Nov 4, 2026.
FDMT is down 1.68% over the past week, down 10.17% over the past month and up 14.23% over the past year. The price is above its 200-day moving average of $10.91.
Of the 12 analysts covering 4D Molecular Therapeutics, Inc., 2 rate it a strong buy, 9 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
4D Molecular Therapeutics, Inc. has a market capitalization of $678.4M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, 4D Molecular Therapeutics, Inc. posted a loss of $1.04 per share against an estimate of -$1.02, missing expectations by 1.96%. Upcoming reports are listed in the earnings calendar.
4D Molecular Therapeutics, Inc. reported revenue of $3.78M in its most recent quarter, which has increased by 25,106.67% compared with the same quarter a year earlier. Analysts had expected $3.62M.
4D Molecular Therapeutics, Inc. has not paid any dividends over the past year.
In the latest trading session FDMT moved between $11.55 and $12.42, a range of 7.08% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of 4D Molecular Therapeutics, Inc. shows a neutral rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks FDMT has traded between $6.96 and $16.93. The current price is 27.47% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.